ReviewJournal of ginseng research2026
Red ginseng-mediated modulation of the NLRP3 Inflammasome in neuroinflammatory-related cognitive impairments.
Review in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NLRP3 inflammasome is a key immune regulator involved in the pathophysiology of neuroinflammation and various neurodegenerative diseases. Recent studies have shown that both activation and inhibition of the NLRP3 inflammasome can influence disease progression and symptoms in models of cognitive impairment, including Alzheimer's disease (AD). Red ginseng (RG), a traditional medicinal plant, possesses anti-inflammatory properties and shows potential for modulating the NLRP3 inflammasome pathway. This review highlights the effects of RG on the NLRP3 inflammasome, with a particular focus on its therapeutic potential in AD and related cognitive impairments. The structure and activation mechanism of the NLRP3 inflammasome are first described, followed by a discussion of its role in neurodegenerative diseases and neuroinflammation. We then explore how RG and its major components regulate the priming and activation phase of the NLRP3 inflammasome, and discuss their therapeutic potential based on findings from the neuroinflammatory-related cognitive impairment model. Furthermore, we identify supporting evidence for the application of the RG-NLRP3 mechanism in other central nervous system disorders (CNS) disorders, such as cerebral ischemia and vascular dementia. Overall, RG emerges as a promising therapeutic candidate for mitigating neuroinflammation and enhancing cognitive function in neuroinflammatory-related cognitive disorders through NLRP3 inflammasome regulation. Future studies using various neurodegenerative disease (NDD) models and clinical trials are necessary to further validate the therapeutic potential of the RG-NLRP3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.